Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,556.00GBp
16 Nov 2018
Change (% chg)

-65.00 (-1.41%)
Prev Close
4,621.00
Open
4,626.00
Day's High
4,650.00
Day's Low
106.50
Volume
986,703
Avg. Vol
2,030,525
52-wk High
4,780.00
52-wk Low
106.50

Latest Key Developments (Source: Significant Developments)

Omega Advisors Cuts Share Stake in Microsoft, Facebook
Wednesday, 14 Nov 2018 10:34am EST 

Nov 14 (Reuters) - Omega Advisors Inc::OMEGA ADVISORS CUTS SHARE STAKE IN ADOBE INC TO 109,400 SHARES FROM 236,600 SHARES.OMEGA ADVISORS INC DISSOLVES SHARE STAKE IN AUTODESK INC - SEC FILING.OMEGA ADVISORS INC CUTS SHARE STAKE IN FACEBOOK INC BY 58.9 PERCENT TO 88,200 CLASS A SHARES.OMEGA ADVISORS INC CUTS SHARE STAKE IN MICROSOFT CORP BY 11.1 PERCENT TO 921,905 SHARES.OMEGA ADVISORS INC UPS SHARE STAKE IN SINCLAIR BROADCAST GROUP INC BY 25.5 PERCENT TO 3.3 MILLION CLASS A SHARES.OMEGA ADVISORS INC CUTS SHARE STAKE IN EASTMAN CHEMICAL CO BY 49.4 PERCENT TO 174,213 SHARES.OMEGA ADVISORS INC CUTS SHARE STAKE IN DISH NETWORK CORP BY 28.5 PERCENT TO 740,722 CLASS A SHARES.OMEGA ADVISORS INC DISSOLVES SHARE STAKE IN SHIRE PLC.OMEGA ADVISORS INC - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Takeda Gets Clearance From Japan Fair Trade Commission For Shire Deal
Thursday, 18 Oct 2018 02:52am EDT 

Oct 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::RECEIVED UNCONDITIONAL CLEARANCE FROM JAPAN FAIR TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE.  Full Article

Shire Says Granted EU Marketing Authorization For Veyvondi For Adults With Von Willebrand Disease
Wednesday, 12 Sep 2018 02:00am EDT 

Sept 12 (Reuters) - Shire PLC ::SHIRE GRANTED EU MARKETING AUTHORIZATION FOR VEYVONDI® FOR ADULTS WITH VON WILLEBRAND DISEASE.MARKETING AUTHORIZATION WILL ENABLE PATIENT ACCESS TO VEYVONDI THROUGHOUT EUROPE.EUROPEAN COMMISSION (EC) HAS GRANTED MARKETING AUTHORIZATION FOR VEYVONDI [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] (RVWF).  Full Article

Shire Buys Switzerland-Based Sanaplasma AG
Thursday, 6 Sep 2018 05:30am EDT 

Sept 6 (Reuters) - Shire PLC ::SHIRE ACQUIRES SANAPLASMA AG BOOSTING PLASMA COLLECTION NETWORK FOR IMMUNOLOGY FRANCHISE.DEAL EXPECTED TO INCREASE CO'S ACCESS TO PLASMA IN LONGER TERM AND ADD TO EUROPEAN PLASMA COLLECTION NETWORK.ACQUISITION IS EXPECTED TO SUPPORT GROWTH OF IMMUNOLOGY BUSINESS.SANAPLASMA AG ADDS 14 NEW CENTRES IN CZECH REPUBLIC AND HUNGARY TO CO'S EUROPEAN-BASED PLASMA COLLECTION NETWORK.  Full Article

Shire Announces FDA Approval For Label Expansion Of Cinryze For Prevention Of Attacks In Pediatric HAE
Thursday, 21 Jun 2018 02:00am EDT 

June 21 (Reuters) - Shire PLC ::SHIRE ANNOUNCES FDA APPROVAL FOR LABEL EXPANSION OF CINRYZE FOR PREVENTION OF ATTACKS IN PEDIATRIC HAE.  Full Article

Takeda Says Entered Into Term Loan Credit Agreement For Up To $7.5 Billion For Shire Acquisition
Friday, 8 Jun 2018 02:01am EDT 

June 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SAYS ENTERED INTO TERM LOAN CREDIT AGREEMENT FOR UP TO $7.5 BILLION FOR SHIRE ACQUISITION.  Full Article

Takeda Pharmaceutical says execution of bridge loan agreement for Shire plc acquisition
Tuesday, 8 May 2018 02:38am EDT 

May 8(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it signed 364-Day Bridge Credit Agreement worth up to $30.85 billion for Shire plc acquisition on May 8 .  Full Article

Takeda Confirms Made A Revised Proposal To Board Of Shire
Tuesday, 24 Apr 2018 09:16am EDT 

April 24 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA STATEMENT REGARDING SHIRE PLC.CONFIRMS THAT IT HAS MADE A REVISED PROPOSAL TO BOARD OF SHIRE .  Full Article

Shire Says FDA Approves Vonvendi For Perioperative Management Of Bleeding In Adult Patients With Von Willebrand Disease
Tuesday, 17 Apr 2018 09:00am EDT 

April 17 (Reuters) - Shire PLC ::FDA APPROVES VONVENDI FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE.  Full Article

Takeda Responds to Media Reports About CEO's Comments On Possible Offer For Shire
Friday, 6 Apr 2018 12:35pm EDT 

April 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::STATEMENT REGARDING PRESS REPORTS.‍NOTES MEDIA REPORTS ABOUT COMMENTS ATTRIBUTED TO TAKEDA'S CEO CHRISTOPHE WEBER REGARDING COMPANY'S POSSIBLE OFFER FOR SHIRE PLC​.‍"CONFIRMS THAT WEBER'S COMMENTS WERE, HOWEVER, ALIGNED WITH STATEMENTS IN OUR PREVIOUS PRESS RELEASES"​.‍ PRIOR STATEMENTS "CLEARLY DEFINED STRATEGIC AND FINANCIAL OBJECTIVES CORE TO ITS DISCIPLINED APPROACH TO ACQUISITIONS".‍"ANY POTENTIAL OFFER FOR SHIRE, IF MADE, WOULD HAVE TO ALIGN WITH THE STRICT INVESTMENT CRITERIA"​.  Full Article

UK Stocks-Factors to watch on Nov 13

Nov 13 Britain's FTSE 100 index is seen opening 15 points higher at 7,068 on Tuesday, according to financial bookmakers. * SHIRE, TAKEDA: Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire, according to documents for the deal published on Monday. * IQE: British chipmaker IQE Plc warned on Monday that its current-year financial results would be lower, after fellow Apple sup